Bell, Christopher F. http://orcid.org/0000-0001-6413-2537
Wu, Benjamin
Huang, Shirley P.
Rubin, Bernard
Averell, Carlyne M.
Chastek, Benjamin
Hulbert, Erin M.
Funding for this research was provided by:
GSK (GSK Study 214102)
Article History
Received: 12 March 2024
Accepted: 29 April 2024
First Online: 31 May 2024
Declarations
:
: All methods were performed in accordance with relevant guidelines and regulations. The analysis relied on secondary retrospective data that was fully de-identified and recorded in a manner where the identity of human subjects could not be ascertained directly or indirectly; and were thus anonymous. Patient-level data (de-identified and anonymized) used in the study were analyzed in compliance with the patient confidentiality requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996. As this study utilized data that was de-identified, anonymized and complied with HIPAA, it was deemed that the study did not require review/approval from an institutional review board or collection of informed consent.
: Not applicable.
: CFB and BR are employees of GSK and hold stocks and shares in the company. BW and CMA are former employees of GSK and held stocks and shares in the company. SPH is a former postdoctoral fellow at GSK and held stocks and shares in the company. BC and EMH are employees of Optum.